Trials / Completed
CompletedNCT02828046
An Ascending Dose Study to Evaluate M281 Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD)
A Phase 1, Single Center, Randomized, Double-Blind, Placebo-Controlled, Single (Part 1) and Multiple (Part 2) Ascending Dose Study to Evaluate the Safety, Tolerability, PK and PD of M281 Administered to Healthy Volunteers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 50 (actual)
- Sponsor
- Momenta Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to evaluate safety, tolerability, and PK/PD of M281 after single and multiple doses in healthy volunteers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | M281 | |
| OTHER | Placebo |
Timeline
- Start date
- 2016-05-09
- Primary completion
- 2017-08-08
- Completion
- 2017-08-08
- First posted
- 2016-07-11
- Last updated
- 2019-10-14
Locations
1 site across 1 country: Netherlands
Source: ClinicalTrials.gov record NCT02828046. Inclusion in this directory is not an endorsement.